Antidiabetic drugs

British Journal of Cardiology

Volumn 10, Issue 2, 2003, Pages 128-136

  Bailey, Clifford J ^a   Day, Caroline ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Acarbose; Antidiabetic drugs; Insul in; Meglitinides; Metabolic syndrome; Metformin; Sulphonylureas; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; ANTIOXIDANT; BIGUANIDE; CHLORPROPAMIDE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG;

ANEMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; EDEMA; ENTEROPATHY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; HYPOGLYCEMIA; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER DISEASE; LIVER TOXICITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; WEIGHT GAIN;

EID: 0037732649     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7.
2. Kannel WB, McGee DC. Diabetes and glucose intolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care 1979;2:120-6.
3. Standl E, Balletshofer B, Dahl B. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner project. Diabetologia 1996;39:1540-5.
4. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-86.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
6. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-85.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
8. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
9. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
10. Standl E. Cardiovascular risk in type 2 diabetes. Diabetes Obes Metab 1999;1(suppl 2):S24-S36.
11. Stratton IM, Alder AI, Neil AW et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): A prospective observational study. BMJ 2000;321:495-512.
12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-13.
13. Bailey CJ. Antidiabetic drugs. Br J Cardiol 2000;7:350-60.
14. DeFronzo RA. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997;5:177-269.
15. Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777-83.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
17. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30.
18. National Institute for Clinical Excellence. Management of Type 2 Diabetes. Management of Blood Glucose. NICE No128. London: National Institute for Clinical Excellence, September 2002.
19. National Institute for Clinical Excellence Management of type 2 diabetes. Management of Blood Pressure and Blood Lipids. NICE No167. London: National Institute for Clinical Excellence, October 2002.
20. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2): S1-S29.
21. Turner RC, Cull CA, Fright V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirements for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.
22. Campbell IW, Bailey CJ. New approaches to glycaemic control in type 2 diabetes. Mod Diabetes Management 2001;2:6-10.
23. Bailey CJ, Campbell IW. United Kingdom Prospective Diabetes Study: Implication for metformin. Br J Cardiol 2002;9:115-19.
24. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety 1994;11:223-41.
25. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
26. + channels an insulin secretion: Role in health and disease. Diabetologia 1999;42:903-19.
27. Muller G, Wied S. The sulfonylurea drug glimepiride stimulates glucose transport, glucose transporters translocation and dephosphorylation in insulin resistant rat adipocytes in vitro. Diabetes 1993;42:1852-67.
28. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16.
29. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin. Therapeutic and cellular mechanisms. Drugs 1999;58(suppl 1):31-9.
30. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:577-9.
31. Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Safety 1999;20:489-503.
32. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-45.
33. Bailey CJ, Day C. Thiazolidinediones today. Br J Diabetes Vasc Dis 2000;1:7-13.
34. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Ann Rev Med 2001;52:239-57.
35. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Application, benefits and risks. Diabetes Rev 1995;3:308-34.
36. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomised, controlled trial. Ann Intern Med 1999;130:389-96.
37. Hermann LS. Combination therapy with insulin and metformin. Endocrine Pract 1998;4:404-12.
38. Wing RR, Shoemaker M, Marcus MDM. Variables associated with weight loss and improvements in glycemic control in type 2 diabetes patients. Arch Intern Med 1990;147:1749-53.
39. Mulcahy HE, Ballinger AB. Orlistat: A new agent for the treatment of obesity. Br J Cardiol 1999;6:276-83.
40. Hollander PA, Elbein SC, Hirsch IB. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomised double-blind study. Diabetes Care 1998;21:1288-94.
41. Day C, Bailey CJ. Sibutramine update. Br J Diabetes Vasc Dis 2002;2:392-7.
42. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-8.